BidaskClub upgraded shares of Impax Laboratories (NASDAQ:IPXL) from a sell rating to a hold rating in a research report sent to investors on Thursday.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald set a $35.00 price target on Impax Laboratories and gave the company a buy rating in a report on Friday, December 15th. Zacks Investment Research upgraded Impax Laboratories from a hold rating to a buy rating and set a $23.00 target price on the stock in a research note on Monday, October 16th. Royal Bank of Canada set a $17.00 target price on Impax Laboratories and gave the stock a hold rating in a research note on Tuesday, October 17th. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the stock a hold rating in a research note on Tuesday, October 17th. Finally, Cowen restated a hold rating and issued a $16.00 target price on shares of Impax Laboratories in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the stock. Impax Laboratories presently has an average rating of Hold and an average price target of $19.62.

Impax Laboratories (NASDAQ:IPXL) traded down $0.25 during midday trading on Thursday, reaching $19.50. The company’s stock had a trading volume of 366,681 shares, compared to its average volume of 925,300. The stock has a market cap of $1,482.27, a PE ratio of -3.16, a PEG ratio of 0.99 and a beta of 1.11. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. Impax Laboratories has a fifty-two week low of $7.75 and a fifty-two week high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. The business had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The firm’s revenue for the quarter was down 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.37 EPS. equities analysts predict that Impax Laboratories will post 0.64 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio raised its holdings in Impax Laboratories by 12.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after purchasing an additional 780 shares during the period. Amalgamated Bank acquired a new position in shares of Impax Laboratories during the third quarter valued at approximately $201,000. Stevens Capital Management LP acquired a new position in shares of Impax Laboratories during the third quarter valued at approximately $203,000. Quantbot Technologies LP raised its holdings in shares of Impax Laboratories by 279.0% during the third quarter. Quantbot Technologies LP now owns 10,031 shares of the specialty pharmaceutical company’s stock valued at $203,000 after acquiring an additional 7,384 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in shares of Impax Laboratories during the second quarter valued at approximately $207,000. 91.54% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Impax Laboratories (IPXL) Rating Increased to Hold at BidaskClub” was posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/impax-laboratories-ipxl-rating-increased-to-hold-at-bidaskclub/1855285.html.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.